Immunic Finalizes 1-for-10 Reverse Stock Split to Meet Financing Obligations

summarizeSummary

Immunic, Inc. has filed the Certificate of Amendment to effect a 1-for-10 reverse stock split, which will become effective on April 27, 2026, primarily to meet obligations under a recent securities purchase agreement.

check_boxKey Events

• Reverse Stock Split Finalized

  Immunic filed a Certificate of Amendment to its certificate of incorporation on April 22, 2026, to effect a 1-for-10 reverse stock split.

• Effective Date Set

  The reverse stock split will become effective, and the company's common stock will begin trading on a post-split basis on the Nasdaq Capital Market, at market open on April 27, 2026.

• Share Reduction

  The split will reduce the number of issued and outstanding shares from approximately 136 million to approximately 13.6 million.

• Financing Requirement

  The reverse split is primarily intended to meet contractual obligations under a securities purchase agreement from February 12, 2026.

auto_awesomeAnalysis

This 8-K filing confirms the finalization and effective date of the previously approved 1-for-10 reverse stock split. While the approval was announced on April 14, 2026, this filing marks the definitive implementation of the corporate action. Reverse stock splits are typically viewed negatively by the market as they often signal a company's struggle to maintain its stock price above exchange minimums or to facilitate further financing. The company explicitly states this split is "primarily intended to allow Immunic to meet its contractual obligations under the securities purchase agreement entered into between the Company and certain institutional and accredited investors on February 12, 2026," highlighting its necessity for ongoing financing. Investors should monitor the stock's performance post-split and any subsequent financing activities.